Compare DGII & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | ANAB |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | DGII | ANAB |
|---|---|---|
| Price | $42.52 | $44.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $48.80 | ★ $58.09 |
| AVG Volume (30 Days) | 300.2K | ★ 431.3K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $430,221,000.00 | $169,467,000.00 |
| Revenue This Year | $10.51 | $135.45 |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $39.67 | ★ N/A |
| Revenue Growth | 1.46 | ★ 196.42 |
| 52 Week Low | $22.39 | $12.21 |
| 52 Week High | $48.00 | $52.47 |
| Indicator | DGII | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 48.56 |
| Support Level | $42.48 | $42.00 |
| Resistance Level | $45.13 | $47.36 |
| Average True Range (ATR) | 1.21 | 2.35 |
| MACD | -0.39 | -0.92 |
| Stochastic Oscillator | 8.14 | 25.12 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).